The present invention relates to a composition which comprises an electron-transporting host and a hole-transporting host, to the use thereof in electronic devices and to electronic devices containing this composition. The electron-transporting host is particularly preferably selected from the class of the triazine-dibenzofuran-carbazole systems or the class of the triazine-dibenzothiophene-carbazole systems. The hole-transporting host is preferably selected from the class of the biscarbazoles.

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: ##STR00001## wherein J.sup.1 and J.sup.2 each represent CH or N, with the proviso that J.sup.1 and J.sup.2 are not simultaneously CH; r represents 0 to 4; each R.sup.101 is the same or different when r is 2 or more, and R.sup.101 represents a C.sub.1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R.sup.102 is the same or different when s is 2 or more, and R.sup.102 represents a halogen atom or the like; R.sup.103 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-6 cycloalkyl group, or a C.sub.3-6 cycloalkyl C.sub.1-6 alkyl group; and R.sup.101 and R.sup.103 are optionally linked together to form a five- to seven-membered ring hetero ring when R.sup.101 is present at the 8-position.

Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: ##STR00001## wherein J.sup.1 and J.sup.2 each represent CH or N, with the proviso that J.sup.1 and J.sup.2 are not simultaneously CH; r represents 0 to 4; each R.sup.101 is the same or different when r is 2 or more, and R.sup.101 represents a C.sub.1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R.sup.102 is the same or different when s is 2 or more, and R.sup.102 represents a halogen atom or the like; R.sup.103 represents a hydrogen atom, a C.sub.1-6 alkyl group, a C.sub.3-6 cycloalkyl group, or a C.sub.3-6 cycloalkyl C.sub.1-6 alkyl group; and R.sup.101 and R.sup.103 are optionally linked together to form a five- to seven-membered ring hetero ring when R.sup.101 is present at the 8-position.

Disclosed herein are embodiments of a compound having a Formula I ##STR00001##
or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. ##STR00002## Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

Disclosed herein are embodiments of a compound having a Formula I ##STR00001##
or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. ##STR00002## Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections. ##STR00001##

This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections. ##STR00001##

The present invention provides compounds of Formula (I):

##STR00001##

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I):

##STR00001##

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.